Multicenter Study Finds Cost Savings Associated With Coronary Interventions Via Transradial (Wrist) Access Exceed $800 Per

 Multicenter Study Finds Cost Savings Associated With Coronary Interventions
 Via Transradial (Wrist) Access Exceed $800 Per Procedure Versus Transfemoral
                                (Groin) Access

Researchers Say Transradial Procedures Could Help U.S. Hospitals Realize
Nearly $50 Million in Annual Cost Savings with Only a Modest 10% Increase in
Transradial Procedures

PR Newswire

SOMERSET, N.J., July 30, 2013

SOMERSET, N.J., July 30, 2013 /PRNewswire/ --A new study finds U.S. hospitals
could experience nearly $50 million in cost savings annually by performing
percutaneous coronary interventions (PCI) through the radial artery of the
wrist (Transradial), rather than the femoral artery in the groin
(Transfemoral). Published online, ahead of print, in JACC: Cardiovascular
Interventions, a peer-reviewed journal of the American College of Cardiology,
the study was supported by an unrestricted research grant from Terumo Medical
Corporation.

The study population consisted of a retrospective cohort of more than 7,000
patients undergoing PCI at five U.S. medical centers from January 1, 2010, to
March 31, 2011. The study was designed to evaluate the costs of using
Transradial Access Intervention (TRI) and Transfemoral Access Intervention
(TFI). Findings show that TRI was associated with a cost savings exceeding
$800 per PCI procedure relative to TFI. Most of these cost savings were driven
by reduced patient length of stay after the procedure and reductions in
bleeding complications.

"Transradial access is clearly an efficacious medical treatment strategy. Many
studies have demonstrated the clinical benefits of transradial access, such as
reduced bleeding and substantially lower patient length of stay," said Steven
P. Marso, MD, Professor of Medicine, University of Missouri, Kansas City at
Mid America Heart Institute, Saint Luke's Health System, and principal
investigator. "However, our study takes it one step further by demonstrating
an overall hospital cost savings exceeding $800 per PCI. These savings
increased to $1,621 in patients at higher risk for bleeding. Annually, a
hospital performing 1,000 PCIs could save an additional $80,000 to $160,000
for every 10 percent increase in their transradial procedures."

"As a market leader, Terumo understands the significant economic benefit that
transradial access offers to the healthcare system. Each year, more than
600,000 U.S. patients undergo a PCI and the number of TRI procedures is
rising," said Chris Pearson, Vice President, Marketing, Terumo Interventional
Systems. "We believe this technique to be the future of coronary
interventions."

According to Pearson, Terumo will continue to invest in world-class
educational activities that support TRI, as well as a product portfolio
designed to deliver clinical and economic value and contribute to better
patient outcomes.

"Terumo's commitment to providing optimal product solutions that help expand
transradial use has never been stronger," said Pearson. "We are expanding our
product portfolio by launching the GLIDESHEATH^® SLENDER, a hydrophilic coated
introducer sheath specifically designed to deliver larger devices through a
smaller radial access. The smaller insertion profile of the product makes it
an optimal solution for smaller arteries. This will allow more patients to
enter the transradial treatment pathway for PCI."

Terumo Interventional Systems
Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation,
is a market leader in minimally-invasive entry site management and lesion
access technologies. TIS offers a complete, solution-based product portfolio
used in advanced coronary, peripheral endovascular and urological treatments
with strategic initiatives in Transradial Access, Complex Coronary
Intervention and Critical Limb Ischemia. TIS combines innovative research and
development with a deep market understanding to create a pipeline of industry
leading devices that deliver clinical value, economic benefit, and enhanced
patient outcomes. Terumo Medical Corporation is part of Tokyo-based Terumo
Corporation, one of the world's leading medical device manufacturers with $4
billion in sales and operations in more than 160 nations.



SOURCE Terumo Interventional Systems

Contact: Robert Murphy, Jitsu Public Relations, Inc., (908) 276-0777,
Contact@jitsuPR.com
 
Press spacebar to pause and continue. Press esc to stop.